ImmuCell Corp (ICCC) 10-K Summary: Fiscal Year Ended December 31, 2024
Business Context and Reporting Period
ImmuCell Corporation is an animal health company focused on dairy and beef cattle, reporting for the fiscal year ended December 31, 2024. The company operates two primary segments: Scours (First Defense® product line for calf immunity) and Mastitis (Re-Tain® for subclinical mastitis treatment). The company is a smaller reporting company and a non-accelerated filer. As of March 21, 2025, there were 8,982,623 shares of common stock outstanding.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Product Sales | $26.5 million | $17.5 million |
| Gross Margin | $7.9 million (30%) | $3.9 million (22%) |
| Net Operating Loss | ($1.6 million) | ($5.7 million) |
| Net Loss | ($2.2 million) | ($5.8 million) |
| Cash and Cash Equivalents | $3.8 million | $1.0 million |
| Total Debt (Net) | $10.5 million | $12.0 million |
| Order Backlog | $4.4 million | $9.4 million |
Note: Gross margin improved significantly in Q4 2024 (37%) following the remediation of production contamination events.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 52% year-over-year, driven by higher production output and the reduction of a significant order backlog that had constrained sales in 2023.
- Production Recovery: The company experienced multiple contamination events from late 2022 through April 2024, resulting in scrapped inventory charges of $407,000 in 2024 (vs. $527,000 in 2023). Production has run without contamination since April 2024.
- Liquidity Improvement: Net cash provided by operating activities turned positive at $358,000 in 2024, compared to a use of $4.7 million in 2023. This was aided by a $2.5 million swing in inventory cash flow (reduction in inventory levels) and a decrease in net loss.
- Capital Raising: The company raised approximately $4.4 million in net proceeds through an At-The-Market (ATM) offering in 2024, issuing 1,228,227 shares.
Guidance, Outlook, and Risks
- Re-Tain® Regulatory Status: The company submitted its fourth submission of the final Chemistry, Manufacturing, and Controls (CMC) Technical Section to the FDA in January 2025. Approval is required before commercial sales can begin. The company plans a "Controlled Launch" strategy to manage market introduction.
- Supply Chain Constraints: The contract for aseptic filling of Re-Tain® Drug Product (DP) by Norbrook expired in November 2024, with labeling/packaging extended through Q1 2026. The company anticipates a supply pause after current inventory is consumed unless a new manufacturer is approved or in-house capabilities are funded.
- Debt Covenants: The company has a minimum Debt Service Coverage (DSC) ratio covenant of 1.35. This covenant was preemptively waived for periods ending through December 31, 2024. Compliance is required for the year ending December 31, 2025.
- Market Outlook: Management aims to exceed $35 million in product sales by approximately 2027. The company is targeting a return to a 40% gross margin as production yields stabilize.
Investor Verification Checklist
- FDA Approval Timeline: Verify the status of the FDA review of the January 2025 CMC submission and the resolution of inspectional observations at the contract manufacturer (Norbrook).
- Debt Covenant Compliance: Monitor the company's ability to meet the 1.35 DSC ratio for the year ending December 31, 2025, given the high debt service obligations ($2.0 million in 2025, $3.7 million in 2026).
- Re-Tain® Manufacturing: Confirm the resolution of the DP filling supply gap post-Q1 2026 and the decision regarding in-house facility investment vs. new contract manufacturing.
- Gross Margin Sustainability: Assess whether the Q4 2024 gross margin of 37% is sustainable or if it was an anomaly due to specific inventory mix or cost factors.
- Customer Concentration: Note that 77% of sales in 2024 were to two large distributors, creating concentration risk.